DLBCL
Episodes
August 16, 2022
Fakhri Reviews Considerations for Second-Line Therapy in DLBCL
By AJMC Staff
Nearly 5 years after approval of the first CAR T-cell therapy, treatment is moving into second line, and patients have more options than ever for diffuse large B-cell lymphoma. How do physicians choose? Bita Fakhri, MD, MPH, hematologist-oncologist at the University of California San Francisco, discusses the process.
August 8, 2022
Dr Paolo Caimi Highlights the Need for Access and Better Treatments in DLBCL
By AJMC Staff
Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue.
July 17, 2022
With Successor to R-CHOP on Horizon, Habermann Says DLBCL Treatment Choices Create “Complicated World”
By AJMC Staff
June 22, 2022
Zelenetz Discusses How to Evaluate Responses to Therapy in DLBCL
By AJMC Staff
Andrew Zelenetz, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, is the current chair of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network (NCCN).
May 22, 2022
Moffitt’s Dr Julio Chavez Discusses New Treatment, Sequencing Options in DLBCL
By AJMC Staff
Julio Chavez, MD, MS, of Moffitt Cancer Center, spoke with The American Journal of Managed Care® (AJMC®) about how new approvals will alter decision making in the treatment of diffuse large B-cell lymphoma (DLBCL).
May 2, 2022
Dr Kami J. Maddocks Highlights Progress of Last 5 Years in DLBCL
By AJMC Staff
Kami J. Maddocks, MD, professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, spoke with The American Journal of Managed Care® (AJMC®) about treatment approaches for diffuse large B-cell lymphoma (DLBCL).
